Reimagining Cell Analysis to Fuel Scientific Discovery
Cytek Biosciences is committed to providing powerful solutions that enable scientists to rapidly, efficiently obtain deep biological insights through high quality, high parametric datasets.
We are on a mission to advance cancer and cell biology research using a powerful cell analysis technique called flow cytometry.
We are satisfying long unmet needs in fields of research such as cancer biology, immunology and genomics – and helping to advance our collective understanding and diagnosis of cancer. Our products are used at many of the world’s most renown pharmaceutical and CRO firms and cancer research institutions.
As a company, we seek to maintain high ethical standards and a culture that values honesty, integrity and transparency in all that we do. Company decisions are driven by what is right for scientific discovery and customer support. We are committed to our employees, to the environment in which we live and to the communities we serve worldwide.
In 2017, we launched our flagship product, the Aurora. Leveraging powerful fiber optic technology and spectral analysis, the Aurora has revolutionized the flow cytometry industry. It is considered the premier flow cytometer, and leads the way in the field of high-parametric cytometry.Read More
40 Color Flow Cytometry
Always ready for new challenges, we continually update and push the boundaries of our flow cytometry solutions. In 2019, using a five-laser Aurora, a team of Cytek scientists developed, optimized, and successfully ran a 40-color application panel in one sample tube. This achievement gives scientists the ability to obtain deeper insights from a limited sample at a fraction of the time and cost, compared to other systems. The Aurora is the world’s first commercialized fluorescence-based flow cytometer to produce high quality 40-color data.Read More
Cytek products have been well received in more than 20 countries across five continents. Our solutions are rapidly gaining traction with scientists and clinicians around the globe: more than 200 of Cytek’s advanced flow cytometry systems have been installed in the field.Read More
Our Certifications and Licenses
Our team has a unique balance of Financial, Technical, and Operational Management experience focused on agile product development and efficient operations. Our Leaders emphasize delivering Customer Value through Technical Innovation and Superior Customer Service
Wenbin Jiang Ph.D.
Ming Yan Ph.D.
Ken Riley, PMP
Join Our Team
Cytek® is a growing company that is always looking for energetic, educated professionals. Expand your possibilities professionally and personally, and join us.View Job Listings
Board of Directors
Wenbin Jiang Ph.D.
Dr. Jiang is a co-founder of Cytek Biosciences, Inc. and a seasoned entrepreneur and inventor. E2O communications was the first company he cofounded in late 1990s, which was acquired by JDS Uniphase in 2004. He is an inventor of more than 90 US patents and an author of 4 book chapters and more than 50 peer reviewed technical papers.
Xin Huang MD Ph.D.
Dr. Xin Huang received his MD from Peking Union Medical College and PhD in Pharmacology and Molecular Sciences from School of Medicine, Johns Hopkins University. He then worked at Boston Consulting Group before he started his VC career in Omaha Capital. In 2012 he joined Cowin Venture and led the firm’s business in Healthcare sector. He has invested about 40 early stage healthcare start-ups in both China and the US during the past several years.
Ming Yan Ph.D.
Dr. Yan is a co-founder of Cytek Biosciences, Inc. with over 20 years of R&D experience in leadership and innovation. Prior to Cytek®, Dr. Yan held research and development positions at AT&T Bell Laboratories, Lawrence Livermore National Labs and BD Biosciences. He is one of the thought-leaders in flow cytometry instrumentation and standardization. Dr. Yan has published several research papers relating to laser spectroscopy and cell analysis in top peer-reviewed journals. He has over a dozen patents and patent pending applications for his innovations.
Jack Ball is CEO and a board member at Solulink Inc. He is President of Tyball Associates, LLC. In addition, he serves on the board of directors of Aquaro Histology, Carterra, Celsee Diagnostics, Cytek Biosciences Inc., NanoCellect Inc. and Swift Bioscience. Most recently he was CCO at Accuri Cytometers, which was sold to Becton Dickinson in March 2011. Prior to Accuri Cytometers, he was CEO of Amnis Corporation, and has also served as CCO for Molecular Probes, Inc. Prior to that he was with Orchid Biosciences as Sr. VP and General Manager and with Amersham Pharmacia Biotech Inc., where he rose to President for North Amercia.
Mr. Feng Deng founded Northern Light Venture Capital (NLVC) in 2005. He has led and backed nearly 200 companies, focusing on 4 main sectors: TMT (technology, media and telecom), clean technology, healthcare and consumer. Prior to NLVC, Feng was a co-founder of NetScreen Technologies, which went public on NASDAQ and was later acquired by Juniper Networks in 2004 for US$ 4.2 billion. Feng is recipient of Ernst & Young Entrepreneur of the Year (2002) and CRN Innovator of the Year (2003) awards. He has extensive technical and managerial experiences in computer, communication and data networking industries. Feng holds BS and MS degrees in electrical engineering from Tsinghua University, a MS degree in computer engineering from the University of Southern California, and a MBA degree from the Wharton School, University of Pennsylvania. He also holds numerous patents of invention in computer system architecture and IC design.
Dr. Yu Fang
Dr. Francine Fang joined 3E Bioventures as partner in May 2015. Prior to 3E Bioventures, Francine worked at Fidelity Growth Partners Asia (FGPA) as venture partner from 2014-2015. She led the investment transactions of Eyebright and Cytoville (Cytek). From 1998 to 2007, Francine worked at Clontech and BD Biosciences as a group leader in R&D for near 10 years in US. She led the assay development for high content screening in BioImaging group at BD Biosciences in San Jose. Before BD acquisition she led the cell biology group at Clontech for the commercialization of multi-color fluorescent proteins and signal transduction product. From 1996 to 1997, Francine worked as a postdoctor in Physiology at University of Medicine and Dentistry of New Jersey. She got Postdoctoral Fellowship from American Heart Association. Francine has Ph.D. degree in Physiology and Neuroscience at University of Medicine and Dentistry of New Jersey and M.D. degree in Medicine at Capital Institute of Medicine in Beijing China.
Dr. Allen Poirson
Dr. Poirson is an experienced life science executive and entrepreneur. Currently the Senior Vice President of Biopharmaceutical Business Development at twoXAR, he previously served as CEO and Chair of Sony Biotechnology. Dr. Poirson's domain expertise includes analytic instruments, computational biotechnology, medical devices, in vitro diagnostics, chemistry, and software. Allen has formal scientific training in neuroscience and has held research positions at Howard Hughes Medical Institute and NASA. Dr. Poirson obtained his PhD from Stanford.
Mr. Yuan Zheng Director and CEO. Worked in Chinese Academy of Preventive Medicine; Founder and General Manager of Former Shanghai Moore Biotech Co., Ltd.; Founder of KMC in 2005.
Scientific Advisory Board
Diether J. Recktenwald Ph.D.
Holden Maecker Ph.D.
Fred Preffer Ph.D.
Dr. rer. nat. Andreas Radbruch
Dr. Bill Telford
United States - West Coast
Fremont, CA 94538-6407
United States - East Coast
Barboursville, VA 22923-2836
1081 JJ, Amsterdam
Phone: +31 (0) 20 765 3440
Fax: +31 (0) 20 765 3448
2-9-1 Ikenohata Taito-ku
Tokyo 110-0008 Japan
Zhangjiang High-Tech Park
Shanghai Pilot Free Trade Zone, 201203